# Single-Ascending Dose Study of MK-2060 in Healthy Chinese Male Adult Participants (MK-2060-009)

> **NCT06843993** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** MK-2060
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06843993
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-01
- **Primary completion:** 2023-10-27
- **Final completion:** 2023-10-27
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06843993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06843993, "Single-Ascending Dose Study of MK-2060 in Healthy Chinese Male Adult Participants (MK-2060-009)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06843993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*